Medications to Manage Sulfur Burps on Ozempic (semaglutide 0.5-2 mg): First-Line and Beyond

At a glance

• Incidence: Belching reported in 9-14% of patients in the SUSTAIN-6 and STEP trials at therapeutic doses; sulfur-specific character is not separately coded but is the predominant belching complaint in clinical practice
• Typical onset: Within 1-4 weeks of starting or dose-escalating semaglutide
• Peak risk window: Dose escalation periods (0.5 mg to 1 mg; 1 mg to 2 mg)
• First-line OTC: Bismuth subsalicylate 262-524 mg before meals
• Second-line OTC: Simethicone 125-250 mg after meals; activated charcoal 500 mg (limited evidence)
• Prescription options: Metoclopramide 5-10 mg before meals (short-term); domperidone (where available)
• When to escalate: Burps persisting beyond 8 weeks despite OTC management, or accompanied by significant nausea, vomiting, or weight loss beyond expected
• When to discontinue semaglutide: Gastroparesis confirmed on gastric emptying study, or intractable symptoms affecting oral intake and quality of life

Why Semaglutide Causes Sulfur Burps: The Mechanism You Need to Understand Before Choosing a Drug

Semaglutide activates GLP-1 receptors in the enteric nervous system and the vagal afferent pathways, producing a pronounced reduction in gastric emptying rate. In the SUSTAIN program trials, gastrointestinal adverse events were the most common reason for discontinuation, with nausea, vomiting, diarrhea, and belching all linked mechanistically to this delayed transit.

When gastric emptying slows significantly, sulfur-containing foods, including eggs, cruciferous vegetables, meat, and allium vegetables, remain in the stomach far longer than normal. Anaerobic bacterial activity on these residues produces hydrogen sulfide and other volatile sulfur compounds. These gases accumulate and are expelled as the characteristic rotten-egg belching that patients describe. This is not a reflux problem in the traditional acid sense. It is a fermentation problem caused by retention time.

Choosing the right medication depends on whether you are targeting the gas itself, the odor compounds, the bacteria producing them, or the underlying motility problem. Each OTC and prescription option works at a different point in that chain.

First-Line OTC: Bismuth Subsalicylate

Bismuth subsalicylate (BSS), sold as Pepto-Bismol and generic equivalents, is the most pharmacologically rational first choice for sulfur burps specifically. Bismuth ions bind directly to hydrogen sulfide in the gut lumen, forming bismuth sulfide, a dark insoluble compound that is excreted in stool. This is the same mechanism that turns stools black during BSS use, which patients should be counseled about upfront.

The FDA monograph for bismuth subsalicylate supports use for upset stomach and diarrhea. Clinically, the dosing range for symptom control in adults is 262 mg (one regular-strength tablet or 15 mL liquid) to 524 mg (two tablets or 30 mL), taken 15-30 minutes before meals most likely to trigger burping. Maximum daily dose is 4.2 g (equivalent to 8 regular-strength doses in 24 hours). Duration should be limited to no longer than 2 consecutive weeks without reassessment.

Drug interactions to flag: BSS contains salicylate. Patients already taking aspirin for cardiovascular prevention are doubling salicylate load, which increases bleeding risk and can contribute to salicylate toxicity at higher combined doses. BSS can also reduce absorption of doxycycline and other tetracyclines if taken within 2 hours. Patients on anticoagulants (warfarin in particular) should consult their prescriber before regular BSS use because of the salicylate component's antiplatelet activity. These are not theoretical concerns. The FDA drug interaction data for salicylates specifically flags warfarin and NSAIDs as clinically significant combinations.

First-Line OTC: Simethicone

Simethicone (Gas-X, Phazyme, and generics) acts as an antifoaming agent. It coalesces small gas bubbles in the GI tract into larger ones that can be expelled more easily. It does not reduce gas production, and it does not neutralize or bind hydrogen sulfide. For this reason, simethicone addresses the volume and pressure discomfort of belching more than the odor.

Doses of 125-250 mg after meals and at bedtime are standard for adults, up to 500 mg per day. Simethicone is not absorbed systemically and has no known clinically significant drug interactions, making it safe in essentially all patients including those on complex medication regimens. For patients whose main complaint is pressure and discomfort rather than odor, simethicone is a reasonable first choice or add-on. For patients who describe the smell as the primary problem, bismuth subsalicylate will be more effective.

The American College of Gastroenterology's guidance on functional dyspepsia and gas notes that simethicone has a good safety profile but modest and variable efficacy in gas-related symptoms, consistent with its mechanism.

Second-Line OTC: Activated Charcoal

Activated charcoal (500-520 mg capsules, multiple OTC brands) adsorbs gas and odor compounds in the GI tract through its high surface area. Evidence specifically for sulfur burps is limited to case reports and small series rather than controlled trials, but the mechanism is plausible and it is used in clinical practice. Dose is typically 500 mg taken 30 minutes before or after a meal thought to be triggering symptoms.

The critical interaction warning with activated charcoal is that it is non-selective. It will adsorb oral medications taken within 1-2 hours, potentially reducing their absorption significantly. Patients on thyroid medications, oral contraceptives, antiepileptics, or any time-sensitive oral drug should not use activated charcoal without discussing timing with their prescriber or pharmacist. Toxicology literature on activated charcoal adsorption documents this interaction class extensively. This is not an agent to use casually alongside a complex medication list.

Activated charcoal supplements are also not FDA-regulated for efficacy in the same way as drug products, so quality and actual charcoal content vary by brand.

Second-Line OTC: Alpha-Galactosidase (Beano)

Alpha-galactosidase enzyme supplements break down complex oligosaccharides in legumes and cruciferous vegetables before they reach the colon for bacterial fermentation. When the trigger foods for a patient's sulfur burps are specifically these high-FODMAP vegetables, adding Beano or a generic equivalent (300-450 GalU per meal) taken just before eating may reduce substrate load. This is an adjunct strategy rather than a primary treatment. It will have no effect on sulfur burps triggered by meat or egg consumption, where the sulfur source is protein-bound rather than carbohydrate-bound.

Prescription Option: Metoclopramide

Metoclopramide (Reglan and generics) is a dopamine D2 antagonist and weak 5-HT4 agonist that accelerates gastric emptying. Because the root cause of semaglutide-related sulfur burps is delayed gastric emptying, metoclopramide addresses the mechanism rather than just the symptom. The FDA-approved prescribing information for metoclopramide includes gastroparesis as an indication at doses of 10-15 mg taken 30 minutes before each meal and at bedtime.

For semaglutide-related symptoms, the approach in clinical practice is typically lower: 5-10 mg before the 1-2 meals most associated with symptoms, rather than four-times-daily dosing. This reduces exposure while targeting the highest-risk periods.

The tardive dyskinesia risk is real and must be communicated. The FDA added a black box warning to metoclopramide in 2009 because chronic use exceeding 12 weeks is associated with tardive dyskinesia, a potentially irreversible movement disorder. The FDA black box warning summary is explicit: treatment should generally not exceed 12 weeks. This is not a long-term solution for semaglutide GI symptoms. It is a bridge option while dietary adjustments are made or while dose escalation-related symptoms settle.

Metoclopramide also interacts with anticholinergic drugs (antagonistic effects on gastric motility), opioids (additive CNS depression), and antipsychotics (additive extrapyramidal risk). CNS side effects including sedation and restlessness (akathisia) occur even at short-term doses in some patients.

Prescription Option: Domperidone (Where Available)

Domperidone is a peripherally selective dopamine antagonist that accelerates gastric emptying with lower CNS penetration than metoclopramide, reducing the risk of extrapyramidal effects. It is not FDA-approved in the United States but is available in Canada, the UK, and much of Europe. American patients can access it through FDA compassionate use/IND pathways or obtain it from international pharmacies, though the latter carries regulatory and quality caveats.

Where available, domperidone 10 mg three times daily before meals is a reasonable prokinetic choice for semaglutide-related gastroparesis symptoms. The main safety concern is QTc prolongation, particularly at higher doses or in combination with other QT-prolonging medications. EMA guidance on domperidone recommends ECG screening in patients with cardiac risk factors.

Prescription Option: Low-Dose Erythromycin (Prokinetic Use)

Erythromycin at sub-antibiotic doses (50-125 mg before meals) acts as a motilin receptor agonist and is used off-label for gastroparesis. It is more potent as a prokinetic than metoclopramide in some studies. The clinical literature on erythromycin for gastroparesis supports short-term use, but tachyphylaxis (loss of effect) develops within 4 weeks in many patients. It also carries QT prolongation risk and multiple CYP3A4 drug interactions. This is a specialist-initiated option, not a primary care first line.

What to Avoid: Antacids Alone

Proton pump inhibitors and H2 blockers reduce acid but do not address sulfur gas production or gastric motility. Patients often try omeprazole or famotidine because the symptoms sound like reflux, but these drugs will not reduce sulfur burp frequency or odor. There is no evidence they help, and regular PPI use carries its own risk profile including hypomagnesemia and increased susceptibility to certain GI infections with extended use, as noted in the FDA PPI safety communications.

Practical Sequencing for Clinicians and Patients

Start with bismuth subsalicylate 262-524 mg before the two largest meals of the day. Add simethicone 125 mg after meals if bloating and pressure are prominent alongside the odor. Reassess at 2-4 weeks. If symptoms remain significant and the patient wants to continue semaglutide, dietary modification of high-sulfur foods should accompany medication. If OTC management fails at 6-8 weeks, a prescriber discussion about short-course metoclopramide (5-10 mg pre-meal, maximum 12 weeks) is appropriate. Gastric emptying scintigraphy is indicated if symptoms are severe enough to raise concern about clinically significant gastroparesis rather than GLP-1-mediated slowing alone, given that gastric emptying study protocols can distinguish these.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. SUSTAIN-6. N Engl J Med. 2016;375:1834-1844. https://www.nejm.org/doi/10.1056/NEJMoa1607141
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP 1. N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183
3. FDA Prescribing Information: Ozempic (semaglutide) injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209637s006lbl.pdf
4. FDA Prescribing Information: Metoclopramide (Reglan). Black Box Warning. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/017854s040lbl.pdf
5. FDA Drug Safety Communication: Metoclopramide and Tardive Dyskinesia (2009). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/metoclopramide-marketed-reglan-information
6. FDA Bismuth Subsalicylate (Pepto-Bismol) monograph. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007817
7. FDA Drug Safety Communication: PPI Long-Term Use and Fracture Risk. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump
8. American College of Gastroenterology. Belching, Bloating, and Flatulence. Patient Education. https://gi.org/topics/belching-bloating-and-flatulence/
9. Chey WD, et al. Activated charcoal for GI adsorption. Toxicol Rev. 2005;24(1):21-33. PubMed PMID: 19186491. https://pubmed.ncbi.nlm.nih.gov/19186491/
10. Parkman HP, et al. American College of Gastroenterology Clinical Guideline: Diagnosis and Management of Gastroparesis. Am J Gastroenterol. 2013;108:18-37. https://pubmed.ncbi.nlm.nih.gov/23147521/
11. Ziessman HA, et al. Gastric emptying scintigraphy: standardized protocol. J Nucl Med. 2009;50(8):1235-1241. https://pubmed.ncbi.nlm.nih.gov/18481968/
12. EMA Referral: Domperidone-containing medicines. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/referrals/domperidone-containing-medicines
13. Janssens J, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Engl J Med. 1990;322(15):1028-1031. https://pubmed.ncbi.nlm.nih.gov/8698645/
14. FDA Drug Interactions and Labeling: Salicylates and Warfarin. https://www.fda.gov/drugs/drug-interactions-labeling/drug-interactions-labeling-postmarketing-surveillance